標(biāo)題：Research Grade Motavizumab 莫維組單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/641.html

名稱：Research Grade Motavizumab莫維組單抗

別名：Motavizumab莫維組單，MEDI-524,NUMAX, NISTmAb, CR9503, Human Respiratory Syncytial Virus (HRSV)

CAS:677010-34-3

貨號(hào)：DVV02803

適用物種：HRSV-A

寄主物種：Humanized

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1, kappa

應(yīng)用：Research Grade Biosimilar

UniProt：P03420

用途范圍：僅用于科研

靶點(diǎn)：F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購(gòu)買(mǎi)聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Motavizumab. PMID: 20065632

Motavizumab for the prevention of respiratory syncytial virus infection in infants. PMID: 19764889

Motavizumab, RSV, and subsequent wheezing. PMID: 27301921

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis. PMID: 36800182

Motavizumab, RSV, and subsequent wheezing - Authors' reply. PMID: 27998592

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. PMID: 20008423

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. PMID: 24356256

Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. PMID: 17961258

Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. PMID: 17990791

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. PMID: 26511956

Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. PMID: 19330726

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. PMID: 24080653

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. PMID: 20519399

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. PMID: 21522037

Structural basis of respiratory syncytial virus neutralization by motavizumab. PMID: 20098425

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. PMID: 29553863

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). PMID: 16793771

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. PMID: 19636278

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. PMID: 19258920

Letter from the editor. PMID: 20065631

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. PMID: 20525274

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. PMID: 21208913

Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. PMID: 21549714

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. PMID: 17362988

Pharmacological management of human respiratory syncytial virus infection. PMID: 32808830

Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia. PMID: 29500665

Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA. PMID: 20943340

Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein. PMID: 35678603

Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. PMID: 21613394

Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. PMID: 20131925

[Anti RS virus drugs]. PMID: 22568137

Backbone and side-chain resonance assignments of the NISTmAb-scFv and antigen-binding study. PMID: 36083574

Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. PMID: 31446622

The long road to protect infants against severe RSV lower respiratory tract illness. PMID: 31105933

Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. PMID: 19651397

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. PMID: 23633336

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. PMID: 28605249

Respiratory syncytial virus disease: update on treatment and prevention. PMID: 21171875

In silico approach towards designing virtual oligopeptides for HRSV. PMID: 25525622

Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. PMID: 19689261

Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. PMID: 22395247

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. PMID: 29470837

A review of palivizumab and emerging therapies for respiratory syncytial virus. PMID: 21831008

New strategies for control of respiratory syncytial virus infection. PMID: 18978532

A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies. PMID: 29541870

An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus. PMID: 34145291

Immunoinformatics aided approach for predicting potent cytotoxic T cell epitopes of respiratory syncytial virus. PMID: 36935101

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PMID: 30789898

Adeno-Associated Virus Vector-Mediated Expression of Antirespiratory Syncytial Virus Antibody Prevents Infection in Mouse Airways. PMID: 34415793

Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. PMID: 19562644